Ser277
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.1.1
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser277  -  AFAP (human)

Site Information
AELEKKLssERPssD   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 2853100

In vivo Characterization
Methods used to characterize site in vivo:
electrophoretic mobility shift ( 9 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 ) , mutation of modification site ( 9 ) , phospho-antibody ( 9 ) , western blotting ( 9 )
Disease tissue studied:
breast cancer ( 3 , 4 , 6 ) , breast ductal carcinoma ( 3 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, triple negative ( 1 , 3 ) , lung cancer ( 6 ) , non-small cell lung cancer ( 6 ) , ovarian cancer ( 3 )
Relevant cell line - cell type - tissue:
A7r5 ('muscle, smooth') ( 9 ) , breast ( 1 , 3 ) , BT-20 (breast cell) ( 6 ) , BT-549 (breast cell) ( 6 ) , Calu 6 (pulmonary) ( 6 ) , COS (fibroblast) ( 9 ) , H2009 (pulmonary) ( 6 ) , H2077 (pulmonary) ( 6 ) , H2887 (pulmonary) ( 6 ) , H322M (pulmonary) ( 6 ) , HCC2279 (pulmonary) ( 6 ) , HCC366 (pulmonary) ( 6 ) , HCC78 (pulmonary) ( 6 ) , HCC827 (pulmonary) ( 6 ) , HeLa (cervical) ( 2 , 7 , 8 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 4 ) , HMLER ('stem, breast cancer') ( 4 ) , Jurkat (T lymphocyte) ( 5 ) , LCLC-103H (pulmonary) ( 6 ) , MDA-MB-231 (breast cell) ( 6 ) , MDA-MB-468 (breast cell) ( 6 ) , NCI-H1568 (pulmonary) ( 6 ) , NCI-H1648 (pulmonary) ( 6 ) , NCI-H2172 (pulmonary) ( 6 ) , NCI-H520 (squamous) ( 6 ) , NCI-H647 (pulmonary) ( 6 ) , ovary ( 3 ) , PC9 (pulmonary) ( 6 )

Upstream Regulation
Putative in vivo kinases:
PKCA (human) ( 9 )
Treatments:
GF109203X ( 9 ) , ischemia ( 3 ) , phorbol_ester ( 9 ) , PP2 ( 9 ) , rottlerin ( 9 ) , safingol ( 9 ) , staurosporine ( 9 )

Downstream Regulation
Effects of modification on biological processes:
cytoskeletal reorganization ( 9 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704
24719451   Curated Info

4

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

5

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

6

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

7

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

8

Dephoure N, et al. (2008) A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A 105, 10762-7
18669648   Curated Info

9

Dorfleutner A, et al. (2008) Phosphorylation of AFAP-110 affects podosome lifespan in A7r5 cells. J Cell Sci 121, 2394-405
18577577   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2019 Cell Signaling Technology, Inc.